iShares Biotechnology ETF
784 hedge funds and large institutions have $7.36B invested in iShares Biotechnology ETF in 2020 Q3 according to their latest regulatory filings, with 97 funds opening new positions, 265 increasing their positions, 229 reducing their positions, and 75 closing their positions.
29% more first-time investments, than exits
New positions opened: 97 | Existing positions closed: 75
16% more repeat investments, than reductions
Existing positions increased: 265 | Existing positions reduced: 229
2% more funds holding
Funds holding: 766 → 784 (+18)
3.05% less ownership
Funds ownership: 83.91% → 80.86% (-3%)
6% less capital invested
Capital invested by funds: $7.8B → $7.36B (-$443M)
29% less funds holding in top 10
Funds holding in top 10: 24 → 17 (-7)
33% less call options, than puts
Call options by funds: $664M | Put options by funds: $986M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$247M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$143M |
| 3 |
N
Natixis
Paris,
France
|
+$67.8M |
| 4 |
Squarepoint
New York
|
+$29.3M |
| 5 |
EP
Edgestream Partners
Princeton,
New Jersey
|
+$24.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$394M |
| 2 |
JP Morgan Chase
New York
|
-$113M |
| 3 |
Barclays
London,
United Kingdom
|
-$73.6M |
| 4 |
JG
Jefferies Group
New York
|
-$70.5M |
| 5 |
CM
Churchill Management
Los Angeles,
California
|
-$56.4M |
IBB Hedge Fund Activity: Q3 2020 in Review
784 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q3 2020, worth a combined $7.36B — down 5.7% from $7.8B a quarter earlier.
Buyers outnumbered sellers: 97 funds opened new IBB positions and 75 closed out — a net gain of 22 holders — while 265 added to existing stakes and 229 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $247M. The largest seller was Goldman Sachs, cutting an estimated $394M.
- 784 institutional investors held iShares Biotechnology ETF (IBB) as of Q3 2020, up from 766 in Q2 2020.
- Funds reported $7.36B of iShares Biotechnology ETF stock for Q3 2020, down 5.7% quarter-over-quarter.
- 97 funds opened new iShares Biotechnology ETF positions in Q3 2020 and 75 closed out, a net change of +22 holders.
- The largest iShares Biotechnology ETF buyer in Q3 2020 was Morgan Stanley, an estimated $247M added.
- The largest iShares Biotechnology ETF seller in Q3 2020 was Goldman Sachs, an estimated $394M sold.
Based on aggregated 13F filings for Q3 2020.